Comparing inspiratory muscle training and Baduanjin exercises for heart health
Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises on Pulmonary Function, Exercise Capacity and Quality of Life in Patients With Hypertrophic Cardiomyopathy
This study tests whether breathing exercises or a special exercise program can help people with hypertrophic cardiomyopathy improve their lung function, exercise ability, and overall quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 51 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istanbul University - Cerrahpasa Academic / other |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT06490250 on ClinicalTrials.gov |
What this trial studies
This study compares the effects of inspiratory muscle training and Baduanjin exercises on pulmonary function, exercise capacity, and quality of life in patients with hypertrophic cardiomyopathy. It involves three groups: a control group, an inspiratory muscle training group using a specialized device, and a Baduanjin exercise group participating in a structured exercise program. Each intervention lasts for 8 weeks, with the aim of identifying effective methods to improve health outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with a left ventricular wall thickness of 15 mm or more and stable symptoms of hypertrophic cardiomyopathy.
Not a fit: Patients with acute heart failure, significant coronary artery disease, or severe comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance pulmonary function and quality of life for patients with hypertrophic cardiomyopathy.
How similar studies have performed: Previous studies have shown benefits of inspiratory muscle training, but the combination with Baduanjin exercises in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Myocardial thickness in any region of the left ventricle is 15 mm or more on echocardiography or cardiac MRI * Clinically and hemodynamically stable (patients with NYHA Class I and II) * Patients over 18 years of age * Patients who provide informed consent Exclusion Criteria: * Acute decompensated heart failure * Decreased ejection fraction (\<40%) * Unstable angina pectoris * Significant coronary artery disease (CAD) * Severe renal dysfunction (estimated glomerular filtration rate \<30 mL/min/m²) * Uncontrolled hypertension (despite medication) * Severe valve disease (moderate-severe aortic stenosis, advanced mitral regurgitation) * Severe neurological disorders causing autonomic dysfunction * Cognitive impairment that prevents communication * Recent fractures, osteoporosis, presence of tumors, pregnancy, or back and spine problems
Where this trial is running
Istanbul
- Istanbul University-Cerrahpasa (IUC) Cardiology Institute — Istanbul, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Rengin Demir, Prof
- Email: rengindemir@yahoo.com
- Phone: +902124592000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.